Femara 2,5 mg ACA Müller

Description

Side effects

As a rule, adverse reactions are mild to moderately pronounced and are mainly related to suppression of estrogen synthesis.

The incidence of adverse reactions is estimated as follows: occurring “very often” – >10%, “frequently” – ≥1 – <10%, “infrequently” – ≥0.1% – <1%, “rarely” – >0.01 – <0.1%, “very rarely” – <0.01%, including isolated reports.

• Infectious and parasitic diseases:

Infrequently – urinary tract infections.

Benign, malignant and unspecified neoplasms (including cysts and polyps):

Infrequently – pain in the area of the tumour.

• Blood and lymphatic system disorders:

Infrequently – leucopenia.

• Immune system disorders:

Frequency unknown – anaphylactic reactions.

• Metabolic and nutritional disorders:

Very often – hypercholesterolaemia; often – anorexia, increased appetite.

• Mental disorders:

Often – depression; infrequently – anxiety (including nervousness), irritability.

• Nervous system disorders:

Often – headache, dizziness; infrequently – drowsiness, insomnia, memory impairment, sensory disturbances (including paresthesia, hypoesthesia), taste perception disorders, episodes of cerebral circulation disorders, carpal tunnel syndrome.

• Visual disorders:

Infrequently – cataract, eye irritation, “blurred” vision.

• Cardiac disorders:

Infrequently – palpitations*, tachycardia, ischaemic heart disease (including first-time or worsening course of existing angina pectoris, angina pectoris requiring surgical intervention, myocardial infarction, myocardial ischaemia).

• Vascular disorders:

Very often – hot flashes (“hot flashes”); frequently – increased blood pressure (BP); infrequently – thrombophlebitis (including thrombophlebitis of superficial and deep veins); rarely – pulmonary embolism, arterial thrombosis, stroke.